- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
Patients and physicians can now access active clinical trials for various cancer types including lung, breast, leukemia and more through the largest clinical trials database
QUILT utilizes GPS Cancer - a unique, comprehensive set of tests integrating quantitative proteomics, and whole genome (DNA) and transcriptome (RNA) sequencing—to provide oncologists with a full molecular profile of each patient’s cancer not only for an initial biopsy before the trial begins, but throughout the trial process to fully understand how each therapy impacts the patient’s tumor activity.
“The accessibility of QUILT trials through the NIH ClinicalTrials.gov
registry allows us to better inform patients and healthcare providers
about immunotherapy based trials now available and enrolling for a
variety of cancers,” stated Dr.
ClinicalTrials.gov is a registry of clinical trials run by the
To find a QUILT clinical trial, visit: https://clinicaltrials.gov/ct2/results?term=QUILT&Search=Search.
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
currently anticipated results. Factors that may cause future results to
differ materially from management’s current expectations include, among
other things, that GPS Cancer may not perform as anticipated, that
sufficient physicians may not adopt GPS Cancer to assist their diagnoses
or that healthcare payers may not provide reimbursement for GPS Cancer
as expected. Our business is subject to numerous additional risks and
uncertainties, including, among others, risks relating to market
acceptance of our products; our ability to successfully launch new
products and applications; competition; our sales, marketing and
distribution capabilities; our planned sales, marketing, and research
and development activities; unanticipated increases in costs or
expenses; and risks associated with international operations.
Information on these and additional risks, uncertainties, and other
information affecting our business and operating results can be found in
our existing and future filings with the
About
About GPS Cancer™
GPS Cancer™ is a comprehensive molecular
profile available through
View source version on businesswire.com: http://www.businesswire.com/news/home/20161208005293/en/
Media Contact
johodson@nantworks.com
Source: